ASCO 2015 Highlights

Michael Kolodziej, MD,  predicts that the greater proliferation of technology, specifically as used as a means for data collection, will have a vital role in patient treatments as well as understanding what the personalized care delivery approach should be.

Michael Kolodziej, MD, speaks to the issue of how clinical oncologists lack an understanding of how payers operate, but that payers can help create a "roadmap" to success for the oncologists when it comes to the evolving model of care.

Michael Kolodziej, MD, points out the large number of key opinion leaders from different industries within health care who come together at the conference, and how that helps to create a well-balanced larger perspective when taking on the subject of value-based cancer care.

Gary Palmer, MD, JD, MBA, MPH points out how a better overall understanding of genomics and the immune system have had in developing oncology therapies.

Gary Palmer, MD, JD, MBA, MPH discusses some of the ways in which this branch of molecular biology is used in developing cancer therapies.

Gary Palmer, MD, JD, MBA, MPH provides an overview of this significant federal initiative.

Gary Palmer, MD, JD, MBA, MPH offers some benefits to attending conferences such as AVBCC.

Dr Edward Garon provides an overview of the main concerns he has in managing patients with NSCLC, citing pseudoprogression as one of the biggest misconceptions.

Dr Suresh Ramalingam discusses the importance of screening for lung cancer and identifies the ideal patients to target for screening.

Dr Suresh Ramalingam examines the factors he considers when making treatment decisions for his patients.